Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation
Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation
复制标题
DOI：
10.1038/leu.2014.314
复制
发表时间：
2015-05-01
期刊：
影响因子：
11.4
通讯作者：
Vago, L.
中科院分区：
文献类型：
--
作者：
Crucitti, L.;Crocchiolo, R.;Vago, L.
错配的人类白细胞抗原（HLA）基因组丢失是近年来发现的异基因造血干细胞移植（HSCT）后白血病免疫逃逸和复发的机制。在这里，我们首先评估了233例连续移植的发生率，危险因素和结果，这些移植来自部分HLA不匹配的相关和无关供体（分别为MMRD和MMUD）。我们记录了84例复发，其中23例HLA丢失。所有HLA丢失均发生在MMRD HSCT后，23例急性髓系白血病患者中有20例HLA丢失复发。在MMRD HSCT后，HLA丢失变异占复发的33%（23/69），发生时间晚于“经典”对应物（中位数：307 vs 88天，P
Genomic loss of the mismatched human leukocyte antigen ( HLA) is a recently described mechanism of leukemia immune escape and relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Here we first evaluated its incidence, risk factors and outcome in 233 consecutive transplants from partially HLA-mismatched related and unrelated donors (MMRD and MMUD, respectively). We documented 84 relapses, 23 of which with HLA loss. All the HLA loss relapses occurred after MMRD HSCT, and 20/23 in patients with acute myeloid leukemia. Upon MMRD HSCT, HLA loss variants accounted for 33% of the relapses (23/69), occurring later than their 'classical' counterparts (median: 307 vs 88 days, P